Обзоры редакции - davaiknam.ru o_O
Главная
Поиск по ключевым словам:
страница 1 ... страница 2страница 3страница 4
Похожие работы
Название работы Кол-во страниц Размер
Еженедельные обзоры 40 7459.37kb.
1 в разделе Арсеньевский городской округ: изложить пункт 6 в следующей... 6 1506.72kb.
Дмитрий Ливанов: «Пропишем стандарт дошкольного образования» в редакции 1 86.22kb.
Научные обзоры роль социально-педагогической поддержки в решении... 1 274.04kb.
Адвокатскаяпалата г. Москв ы 1 96.58kb.
Обзоры перспективных товарных рынков страны пребывания 1 109.19kb.
5 за 2011 год Обзоры Фенотипические и функциональные характеристики... 1 37.68kb.
Производство рекламных макетов: часто задаваемые вопросы 1 35.85kb.
Обзоры современной физики, том 74, январь 2002 Статистическая механика... 5 546.75kb.
Программа выездной сессии редакции журнала «Дружба народов» 1 22.82kb.
Название: Ain*ol Fire. 5100 руб+% 1 16.63kb.
马克思主义、列宁主义、毛泽东思想、邓小平理论 A74 / М92 / Мухин,Ю. И 6 843.44kb.
Направления изучения представлений о справедливости 1 202.17kb.

Обзоры редакции - страница №4/4


  • Shioda T, Levy JA, Cheng-Mayer C. Macrophage and T-cell line tro- pisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 1991; 349:167-169.

  • Saez-Cirion A, Pancino G, Sinet M, Venet A, Lambotte O. HIV con­trollers: how do they tame the virus? Trends Immunol 2007; 28:532- 540.

  • Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection without immunologic progression. AIDS 1994; 8:1123-1128.

  • Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunop- athogenesis of human immunodeficiency virus infection. N Engl J Med 1993; 328:327-335.

  • Romeria F, Gabriel MN, Margolis DM. Repression of human immu­nodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF. J Virol 1997; 71:9375-9382.

  • Levy JA. The search for the CD8R cell anti-HIV factor (CAF). Trends Immunol 2003; 24:628-632.

  • Sheridan PL, Mayall TP, Verdin E, Jones KA. Histone acetyl-trans- ferases regulate HIV-1 enhancer activity in vitro. Genes Dev 2005; 11:3327-3340.

  • Sagot-Lerolle N, Lamine A, Chaix ML, et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 2008; 22:1125-1129.

  • Espert L, Denizot M, Grimaldi M, et al. Autophagy is involved in T cell death after binding of HIV-1 envelope proteins to CXCR4. J Clin Invest 2006; 116:2161-2172.

  • Zinkernagel RM, Hengartner H. T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS. Im­munol Today 1994; 15:262-268.

    1. McCune JM. The dynamics of CD4R T-cell depletion in HIV disease. Nature 2001; 410:974-979.

    2. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4R T-cell deple­tion in gut lymphoid tissue during primary human immunodeficiency type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003; 77:11708-11717.

    3. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371.

    4. Giorgi JV, Liu Z, Hultin LE, et al. Elevated levels of CD38R CD8R T cells in HIV infection add to the prognostic value of low CD4R T cell levels: results of 6 years of follow-up. J Acquir Immune Defic Syndr 1993; 6:904-912.

    5. Ascher MS, Sheppard HW. AIDS as immune system activation. II. The panergic imnesia hypothesis. J Acquir Immune Defic Syndr 1990; 3:177-191.

    6. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. Pathogen­esis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 2006; 12:289-295.

    7. Sodora DL, Silvestri G. Immune activation and AIDS pathogenesis. AIDS 2008; 22:436-446.

    8. Ameisen JC. Programmed cell death (apoptosis) and cell survival regulation: relevance to AIDS and cancer. AIDS 1994; 8:1197-1213.

    9. Effros RB. Replicative senescence: the final stage of memory T cell differentiation? Curr HIV Res 2003; 1:153-165.

    10. Estes JD, Gordon SN, Zeng M, et al. Early resolution of acute immune activation and induction of PD-1 in SIV-infected sooty mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus macaques. J Immunol 2008; 180:6798-6807.

    11. Silvestri G, Paiardini M, Pandrea I, Lederman MM, Sodora DL. Un­derstanding the benign nature of SIV infection in natural hosts. J Clin Invest 2007; 117:3148-3154.

    12. Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T- cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 2008; 112:2826-2835.

    13. Herbeuval JP, Shearer GM. HIV-1 immunopathogenesis: how good interferon turns bad. Clin Immunol 2007; 123:121-128.

    14. Mandl JN, Barry AP, Vanderford TH, et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and non-pathogenic AIDS virus infections. Nat Med 2008; 14:1077- 1087.

    15. Kannangara S, DeSimone JA, Pomerantz RJ. Attenuation of HIV-1 infection by other microbial agents. J Infect Dis 2005; 192:1003- 1009.

    16. Almeida JR, Price DA, Papagno L, et al. Superior control of HIV-1 replication by CD8R T cells is reflected by their avidity, polyfunc­tionality, and clonal turnover. J Exp Med 2007; 204:2473-2485.

    17. Summerfield JA, Ryder S, Sumiya M, et al. Mannose binding pro­tein gene mutations associated with unusual and severe infections in adults. Lancet 1995; 345:886-889.

    18. Mangano A, Rocco C, Marino SM, et al. Detrimental effects of mannose-binding lectin (MBL2) promoter genotype XA/XA on HIV- 1 vertical transmission and AIDS progression. J Infect Dis 2008; 198:694-700.

    19. Burt TD, Agan BK, Marconi VC, et al. Apolipoprotein (apo) E4 en­hances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc Natl Acad Sci U S A 2008; 105:8718-8723.

    20. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418:646-650.

    21. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003; 9:1404-1407.

    22. Ulenga NK, Sarr AD, Thakore-Meloni S, et al. Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F. J Infect Dis 2008; 198:486-492.




    1. Chiu YL, Soros VB, Kreisberg JF, et al. Cellular APOBEC3G restricts HIV-1 infection in resting CD4R T cells. Nature 2005; 435:108-114.

    2. Stremlau M, Owens CM, Perron Mj, et al. The cytoplasmic body component TRIM5a restricts HIV-1 infection in old world monkeys. Nature 2004; 427:848-853.

    3. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451:425-430.

    4. Varthakavi V, Heimann-Nichols E, Smith RM, et al. Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu. Nat Med 2008; 14:641-647.

    5. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944-947.

    6. Konig R, Zhou Y, Elleder C, et al. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 2008; 135:49-60.

    7. Brass AL, Dykxhoorn DM, Benita Y, et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008; 319:921-926.

    8. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801.

    9. Fust G, Ujhelyi E, Hidvegi T, et al. The complement system in HIV disease. Immunol Invest 1991; 20:231-241.

    10. Hart ML, Saifuddin M, Uemura K, et al. High mannose glycans and siliac acid on gp120 regulate binding of mannose-binding lectin (MBL) to HIV type 1. AIDS Res Hum Retroviruses 2002; 18:1311- 1317.

    11. Wada M, Wada NA, Shirono H, et al. Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication. Biochem Biophys Res Commun 2001; 284:346-351.

    12. Munch J, Standker L, Adermann K, et al. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 2007; 129:263-275.

    13. Rodman TC, Lutton JD, Jiang S, Al-Kouatly HB, Winston R. Circu­lating natural IgM antibodies and their corresponding human cord blood cell-derived Mabs specifically combat the Tat protein of HIV. Exp Hematol 2001; 29:1004-1009.

    14. Lobo PI, Schlegel KH, Yuan W, Townsend GC, White JA. Inhibition of HIV-1 infectivity through an innate mechanism involving natu­rally occurring IgM antileukocyte autoantibodies. J Immunol 2008; 180:1769-1779.

    15. Gomez MB, Hildreth JEK. Antibody to adhesion molecule LFA-1 enhances plasma neutralization of human immunodeficiency virus type 1. J Virol 1995; 69:4628-4632.

    16. Rizzuto CD, Sodroski JG. Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol 1997; 71:4847-4851.

    17. Wang SK, Liang PH, Astronomo RD, et al. Targeting the carbohy­drates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci U S A 2008; 105:3690-3695.

    18. Burton DR, Stanfield RL, Wilson IA. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A 2005; 102:14943- 14948.

    19. Salzwedel K, Smith ED, Dey B, Berger EA. Sequential CD4-corecep- tor interactions in human immunodeficiency virus type 1 Env func­tion: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J Virol 2000; 74:326-333.

    20. Decker JM, Bibollet-Ruche F, Wei X, et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005; 201:1407-1419.

    21. Ahmad R, Sindhu ST, Toma E, et al. Evidence for a correlation be­tween antibody-dependent cellular cytotoxicity-mediating anti- HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol 2001; 21:227-233.

    1. Homsy J, Meyer M, Levy JA. Serum enhancement of human immu­nodeficiency virus (HIV) correlates with disease in HIV infected in­dividuals. J Virol 1990; 64:1437-1440.

    2. Morrow WJW, Isenberg DA, Sobol RE, Strieker RB, Kieber-Emmons T. AIDS virus infection and autoimmunity: A perspective of the clini­cal, immunological, and molecular origins of the autoallergic pa­thologies associated with HIV disease. Clin Immunol Immunopathol 1991; 58:163-180.

    3. Banchereau J, Steinman RM. Dendritic cells and the control of im­munity. Nature 1998; 392:245-252.

    4. Donaghy H, Stebbing J, Petterson S. Antigen presentation and the role of dendritic cells in HIV. Curr Opin Infect Dis 2004; 17:1-6.

    5. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005; 23:275-306.

    6. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284:1835-1837.

    7. Schmidt B, Scott I, Whitmore RG, et al. Low-level HIV infection of plasmacytoid dendritic cells: onset of cytopathic effects and cell death after PDC maturation. Virology 2004; 329:280-288.

    8. Soumelis V, Scott I, Gheyas F, et al. Depletion of circulating natu­ral type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 2001; 98:906-912.

    9. Killian MS, Fujimura S, Hecht FM, Levy JA. Similar changes in plas­macytoid dendritic cell and CD4R T cell counts during primary HIV- 1 infection and treatment. AIDS 2006; 20:1247-1252.

    10. Malleret B, Maneglier B, Karlsson I, et al. Primary infection with sim­ian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I IFN and immune suppression. Blood 2008. [Epub ahead of print].

    11. Kottilil S, Shin K, Planta M, et al. Expression of chemokine and in­hibitory receptors on natural killer cells: effect of immune activation and HIV viremia. J Infect Dis 2004; 189:1193-1198.

    12. Martin MP, Qi Y, Gao X, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39:733-740.

    13. Godfrey Dl, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004; 114:1379-1388.

    14. Moser B, Brandes M. Gammadelta T cells: an alternative type of pro­fessional APC. Trends Immunol 2006; 27:112-118.

    15. Norris PJ, Moffett HF, Yang OO, et al. Beyond help: direct effector functions of human immunodeficiency virus type 1-specific CD4R T cells. J Virol 2004; 78:8844-8851.

    16. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferen­tially maintain highly functional HIV-specific CD8R T-cells. Blood 2006; 107:4781-4789.

    17. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1- specific CD4R T cell responses associated with control of viremia. Science 1997; 278:1447-1450.

    18. Kalams SA, Buchbinder SP, Rosenberg ES, et al. Association be­tween virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 1999; 73:6715-6720.

    19. Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lymphocytes in­hibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A 1994; 91:3764-3768.

    20. Khana KM, Lepisto AJ, Hendricks RL. Immunity to latent viral in­fection: many skirmishes but few fatalities. Trends Immunol 2004; 25:230-234.

    21. Iversen AC, Norris PS, Ware CF, Benedict CA. Human NK cells in­hibit cytomegalovirus replication through a noncytolytic mechanism involving lymphotoxin-dependent induction of IFN-beta. J Immunol 2005; 175:7568-7574.

    22. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cy­totoxic T lymphocytes and plasma load of viral RNA. Science 1998; 279:2103-2106.




    1. Kiepiela P, Ngumbela K, Thobakgale C, et al. CD8(R) T-cell respons­es to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46-53.

    2. Lieberman J. Tracking the killers: how should we measure CD8 T cells in HIV infection? AIDS 2004; 18:1489-1493.

    3. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV- specific T cells is associated with T-cell exhaustion and disease pro­gression. Nature 2006; 443:350-354.

    4. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8 R T cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198-1202.

    5. Price DA, Goulder PJR, Klenerman P, et al. Positive selection of HIV- 1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A 1997; 94:1890-1895.

    6. Yang OO. Aiming for successful vaccine-induced HIV-1-specific cy­totoxic T lymphocytes. AIDS 2008; 22:325-331.

    7. Kinter AL, Hennessey M, Bell A, et al. CD25(R)CD4(R) regulatory T cells from the peripheral blood of asymptomatic HIV-infected in­dividuals regulate CD4(R) and CD8(R) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med 2004; 200:331-343.

    8. Chougnet CA, Shearer GM. Regulatory T cells (Treg) and HIV/ AIDS:summaryof the September 7-8, 2006 Workshop. AIDS Res Hum Retroviruses 2007; 23:945-952.

    9. Kornfeld C, Ploquin MJ, Pandrea I, et al. Antiinflammatory profiles during primary SIV infection in African green monkeys are associat­ed with protection against AIDS. J Clin Invest 2005; 115:1082-1091.

    10. Smith TR, Kumar V. Revival of CD8R Treg-mediated suppression. Trends Immunol 2008; 29:337-342.

    11. Shearer GM, Clerici M. Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today 1996; 17:21-24.

    148.Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infec­tion in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-725.

    1. Kebba A, Kaleebu P, SerwangaJ, etal. HIV type 1 antigen-responsive CD4R T-lymphocytes in exposed yet HIV type 1 seronegative Ugan­dans. AIDS Res Hum Retroviruses 2004; 20:67-75.

    2. Rowland-Jones SL, McMichael A. Immune responses in HIV-ex- posed seronegatives: have they repelled the virus? Curr Opin Im­munol 1995; 7:448-455.

    3. Scott-Algara D, Truong LX, Versmisse P, et al. Increased NK cell activity in HIV-1 exposed but uninfected Vietnamese intravascular drug users. J Immunol 2003; 171:5663-5667.

    1. Jennes W, Verheyden S, Demanet C, et al. Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J Immunol 2006; 177:6588-6592.

    2. Devito C, Broliden K, Kaul R, et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells, j Immunol 2000; 165:5170-5176.

    3. Miyazawa M, Lopalco L, Mazzotta F, et al. Factors modulating sus­ceptibility to HIV infection: the «immunological advantage» of HIV- exposed seronegative individuals. AIDS 2009 (in press).

    4. Stranford S, Skurnick J, Louria D, et al. Lack of infection in HIV-ex- posed individuals is associated with a strong CD8R cell noncytotoxic anti-HIV response. Proc Natl Acad Sci U S A 1999; 96:1030-1035.

    5. Burgener A, Boutilier J, Wachihi C, et al. Identification of differen­tially expressed proteins in the cervical mucosa of HIV-1-resistant sex workers. J Proteome Res 2008; 7:4446-4454.

    6. McNeely TB, Dealy M, Dripps DJ, et al. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodefi­ciency virus 1 activity in vitro. J Clin Invest 1995; 96:456-464.

    7. Levy JA. HIV research: a need to focus on the right target. Lancet 1995; 345:1619-1621.

    8. Sarkar I, Hauber I, Hauber J, Buchholz F. HIV-1 proviral DNA exci­sion using an evolved recombinase. Science 2007; 316:1912-1915.

    9. Levy JA. What can be achieved with an HIV vaccine? Lancet 2001; 357:223-224.

    10. Hoover EA, Mullins Jl, Chu HJ, Wasmoen TL. Development and test­ing of an inactivated feline leukemia virus vaccine. Semin Vet Med Surg (Small Anim) 1995; 10:238-243.

    11. Uhl EW, Heaton-Jones TG, Pu R, Yamamoto JK. FIV vaccine develop­ment and its importance to veterinary and human medicine:a review FIV vaccine 2002 update and review. Vet Immunol Immunopathol 2002;90:113-132.

    12. van de Wijgert JH, Shattock RJ. Vaginal microbicides: moving ahead after an unexpected setback. AIDS 2007; 21:2369-2376.

    13. Cohen MS, GayC, Kashuba AD, Blower S, Paxton L. Narrative re­view: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146:591-601.

    14. Levy JA, Ziegler J. Acquired immune deficiency syndrome (AIDS) is an opportunistic infection and Kaposi's sarcoma results from sec­ondary immune stimulation. Lancet 1983; ii:78—81.

    15. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4:762-774.

    << предыдущая страница  



    • Добропорядочные американцы после смерти отправляются в Париж. Томас Голд Эпплтон (а за ним
    ещё >>